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Introduction: Posttransplant lymphoproliferative disorder (PTLD) is a serious complication following solid organ or
hematopoietic stem cell transplantation (HSCT). Although extranodal involvement of PTLD is common, its isolated
involvement in the central nervous system (CNS) is extremely rare. To date, primary CNS-PTLD has been reported in
13 patients who underwent allogeneic HSCT, but no cases have been reported in autologous HSCT recipients.
Case Description: Herein, we report the first report of a patient with neuroblastoma that progressed to CNS-PTLD after
autologous peripheral blood stem cell transplantation (auto-PBSCT). A 27-month-old boy with stage IV neuroblastoma of
the left adrenal gland received auto-PBSCT after intensive chemotherapy, tumor resection, and radiation of tumor bed
and regional lymph node. An intracranial tumor in his left parietal lobe was detected by magnetic resonance imaging
99 days posttransplantation, and the tumor was completely resected. The histological diagnosis of the intracranial tumor
was diffuse large B-cell lymphoma with latency type III Epstein-Barr virus infection. The patient has maintained tumor free
status 3 years after auto-PBSCT.
Discussion and Evaluation: Given the rarity of CNS-PTLD, there is no consensus on the optimal treatment. Historically,
the outcome of CNS-PTLD has been very poor. However, our patient remains free from PTLD after only total resection.
The prognosis for PTLD following auto-HSCT may depend upon the underlying malignancy, immune state, EBV immune
status, and treatments.
Conclusions: The outcome of PTLD following auto-HSCT is not necessarily poor prognosis. Further research is required to
establish the optimal treatment strategy for CNS-PTLD.
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Posttransplant lymphoproliferative disorder (PTLD) is
one of the possible life-threatening complications follow-
ing solid organ or hematopoietic stem cell transplant-
ation (HSCT). The incidence of PTLD is dependent on
the type of transplanted organ, the type and intensity of
immunosuppression, and the patient’s immune status to
Epstein–Barr virus (EBV) (Lim et al., 2006; Gottschalk
et al., 2005). Following allogeneic HSCT (allo-HSCT),
the risk factors associated with PTLD are donor T-cell
depletion, the use of anti-thymocyte globulin (ATG), un-
related or human leukocyte antigen (HLA)-mismatched
grafts, and acute or chronic graft-versus-host disease
(Landgren et al., 2009). PTLD typically occurs after
prolonged and profound immunosuppression, which
decreases the number of EBV-specific cytotoxic T-
lymphocytes, resulting in uncontrolled EBV-induced
B-lymphocyte proliferation (Penn, 1994).
Extranodal involvement is common in PTLD, but the
isolated involvement of the central nervous system
(CNS) is extremely rare. CNS involvement occurs in ap-
proximately 10–20% of solid organ transplant recipients
(Penn and Porat, 1995; Buell et al., 2005; Cavaliere et al.,
2010). To date, primary CNS-PTLD (PCNS-PTLD) has
been reported in 13 patients who underwent allo-HSCT,
but no cases have been reported in autologous HSCT
(auto-HSCT) recipients (Lieberman et al., 2012; Eckrich
et al., 2012).
Given the rarity of PCNS-PTLD, there is no consensus
about the optimal treatment. In solid organ transplant
recipients, the median time from transplantation to
PCNS-PTLD is 4.4 years (Cavaliere et al., 2010). Con-
versely, the incidence of PTLD peaks within the first
year following allo-HSCT (Landgren et al., 2009).
Herein, we report the first case of PCNS-PTLD in an
infant following auto-HSCT for neuroblastoma.
Case description
A 20-month-old boy was admitted to our hospital for
stage IV neuroblastoma involving the left adrenal gland,
left neck lymph nodes, and bone marrow of the right
femur. No abnormal lesions were detected on a computed
tomography scan of the brain. The patient underwent 5 cy-
cles of chemotherapy consisting of cyclophosphamide
(1,200 mg•m − 2•dose − 1 × 2 days (excluding first cycle;
1 day) ), vincristine (1.5 mg•m − 2•dose − 1 × 1 day), pirar-
ubicin (40 mg•m − 2•dose − 1 × 1 day), and cisplatin
(20 mg•m − 2•dose − 1 × 5 days). After the third and fourth
cycles of the chemotherapy, peripheral blood stem cells
were harvested, and the primary tumor (i.e., the left ad-
renal gland) was completely resected. After 1 more cycle
of chemotherapy, when the patient was 27 months old,
autologous peripheral blood stem cell transplantation
(auto-PBSCT) was performed. The conditioning regimenconsisted of carboplatin (400 mg•m − 2•dose − 1 × 4 days),
etoposide (200 mg•m − 2•dose − 1 × 4 days), and melpha-
lan (100 mg•m − 2•dose − 1 × 2 days). The patient received
an infusion of 1.76 × 106 CD34+ cells/kg of autologous un-
manipulated peripheral blood stem cells, and achieved
neutrophil engraftment on day 12. Starting on day 49 after
auto-PBSCT, the patient received abdominal involved field
radiation of 19.8 Gy in 11 fractions. After treatment, the
patient vomited 2 or 3 times per week, usually in the
morning. The reasons for the vomiting were investigated.
An upper gastrointestinal series was performed, and gas-
troesophageal reflux disease was detected. The patient was
administered famotidine, and the vomiting ceased. Subse-
quently, magnetic resonance imaging on day 99 after
auto-PBSCT revealed an intracranial tumor in the left par-
ietal lobe, and the tumor was accompanied by extensive
peritumoral edema (Figure 1). The tumor was completely
resected. The resected tumor contained a lymphoid infil-
trate composed of many large atypical lymphocytes with
prominent nuclei. Immunohistochemical analysis demon-
strated that the large lymphocytes exhibited a B-cell
phenotype, with positive immunoreactivity for CD20,
CD79a, and MUM-1, and negative staining for CD3 and
CD45RO. Immunohistochemistry showed expression of
EBV nuclear antigen-2 (Figure 2B), and latent membrane
protein 1 in the lymphocytes, and in situ hybridization
indicated nuclear expression of EBV-encoded RNA-1
(Figure 2C). The pathological diagnosis was diffuse large
B-cell lymphoma with latent type III EBV-infection. A
final diagnosis of diffuse large B-cell lymphoma with EBV
associated PTLD was made. EBV statuses were examined
after diagnosis of PTLD. EBV-EA IgG antibody and
EBV-VCA IgM were negative, but EBV-VCA IgG and
EBV-EBNA IgG were positive. EBV-DNA in blood has not
been detected. And, absolute CD4, CD8, and lympho-
cyte count were 174/μl, 470/μl, and 1,460/μl, respectively
(CD4/CD8 ratio; 0.37). The patient has no neurological
symptoms and remains free from neuroblastoma and
EBV-associated PTLD 3 years after auto-PBSCT.
Discussion
PCNS-PTLD was first reported by Schneck and Penn in
1970 (Schneck and Penn, 1970). Since then, the fre-
quency of transplantation has increased, and improve-
ments in supportive care and immunosuppression have
been made. CNS-PTLD is a rare but important compli-
cation in graft patients, particularly in HSCT recipients.
It has been reported that the incidence of PTLD after
allo-HSCT is 0.47–1% (Landgren et al., 2009; Curtis
et al., 1999). Lieberman et al. have reviewed 13 patients
with PCNS-PTLD following allo-HSCT (Lieberman
et al., 2012), and Eckrich et al. have reviewed the inci-
dence of PTLD following pediatric auto-HSCT (Eckrich
et al., 2012). In their report, Eckrich et al. indicate that
Figure 1 T2-weighted magnetic resonance imaging revealed an intracranial tumor in the left parietal lobe, accompanied by extensive
peritumoral edema.
Figure 2 Histological analysis of the brain tumor demonstrated an abnormal infiltration of pleomorphic lymphoid cells with a dominant
component of large lymphoid cells (A; hematoxylin-eosin stain). Nuclear expressions for Epstein–Barr virus (EBV) nuclear antigen 2 (EBNA-2) and
EBV-encoded RNA 1 (EBER1) were detected with immunohistochemistry (B) and in situ hybridization (C), respectively. The pathological diagnosis was
diffuse large B-cell lymphoma with latency type III, EBV-infection.
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(5 cases), retinoblastoma (1 case), nodular sclerosis
Hodgkin’s lymphoma (1 case), and unspecified disease (1
case). Our case of infantile PCNS-PTLD after auto-HSCT
is extremely rare, and no similar case has been reported.
Landgren et al. have indicated that the risk factors
associated with PTLD following allo-HSCT are T-cell
depletion of the donor marrow, ATG use, and unrelated
or HLA mismatched grafts (Landgren et al., 2009). How-
ever, because of the scarcity of the disease, the risk fac-
tors for PTLD following auto-HSCT remain undefined.
EBV infection is a common risk factor for PTLD. In our
case, histopathological analysis revealed that EBV infec-
tion was the etiology of PTLD, although it was unclear
when the patient was infected with EBV. The prognosis
for PTLD following auto-HSCT may depend upon the
underlying malignancy, immune state, EBV immune sta-
tus, and treatments.
Given the rarity of PCNS-PTLD, there is no consensus
on the optimal treatment. Historically, the outcome of
PCNS-PTLD has been very poor. Buell et al. have re-
ported that radiotherapy is the only effective therapy
(Buell et al. 2005). Chemotherapies, including rituximab,
are not effective because of the blood-brain barrier; the
level of rituximab in the cerebrospinal fluid has been
reported to be approximately 0.1% of serum levels
(Rubenstein et al., 2003). In their report, Eckrich et al.
indicate that 4 of 7 patients with PTLD after auto-HSCT
received rituximab (Eckrich et al. 2012). All these pa-
tients underwent a successful resolution of their PTLD,
but 3 died from their underlying malignancies. Recently,
some trials have been conducted in which intrathecal
(van de Glind et al., 2008) or mass administration
(Traum et al, 2006) of rituximab was performed. How-
ever, although these treatments may be promising for
patients with CNS-PTLD, further research is required to
establish the optimal treatment strategy.
Conclusions
The outcome of PTLD following auto-HSCT is not ne-
cessarily poor prognosis. Further research is required to
establish the optimal treatment strategy for CNS-PTLD.
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